Product Description
Mechanisms of Action: RNA polymerase Inhibitor,RNA Synthesis Inhibitor,Protein Synthesis Inhibitor
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Greece | Ireland | New Zealand | South Africa
Approved Indications: None
Known Adverse Events: None
Company: National Cancer Institute (NCI)
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Gastrointestinal Cancer|Lung Cancer|Esophageal Cancer|Digestive System Cancer|Breast Cancer|Mesothelioma|Sarcoma, Ewing|Sarcoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
16-C-0152 | P2 |
Terminated |
Esophageal Cancer|Sarcoma|Mesothelioma |
2019-12-06 |
|
12-C-0151 | P2 |
Terminated |
Gastrointestinal Cancer|Mesothelioma|Breast Cancer|Esophageal Cancer|Lung Cancer|Digestive System Cancer |
2019-08-20 |
|
12-C-0135 | P2 |
Terminated |
Sarcoma, Ewing |
2014-05-21 |